Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLN · Real-Time Price · USD
28.13
+0.71 (2.59%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Avalyn Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Focused on inhaled therapies for pulmonary fibrosis, the company leverages a patented nebulizer and strong IP to address major unmet needs in a large market. Lead candidates show improved tolerability and efficacy, with pivotal data expected next year and a robust pipeline advancing.
-
The company is advancing inhaled therapies for pulmonary fibrosis, aiming to improve tolerability and efficacy over current oral treatments. Key programs are in late-stage clinical trials, with strong long-term data and a robust financial position to support further development and potential market leadership.